Allergic Asthma Clinical Trial
Official title:
Bronchial Provocation Tests With House Dust Mite in Allergic Asthma in Guangzhou
Verified date | February 2018 |
Source | Guangzhou Institute of Respiratory Disease |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to establish the methodology of bronchial provocation tests with house dust mites in China, and to evaluate its safety and effects on upper and lower airways inflammation.
Status | Completed |
Enrollment | 30 |
Est. completion date | February 1, 2018 |
Est. primary completion date | July 1, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 60 Years |
Eligibility |
Inclusion Criteria: - Clinical diagnosis of asthma; - Sensitive to house dust mite; - Stable for more than 4 weeks with FEV1=70%pred Exclusion Criteria: - exacerbation within 3 months; - upper airway infections within 6 weeks; - concomitant of hypertension or heart diseases; - pregnancy |
Country | Name | City | State |
---|---|---|---|
China | Guangzhou institute of respiratory disease | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Guangzhou Institute of Respiratory Disease | Firestone Institute for Respiratory Health |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | correlate of IL-4,IL-13,periostin with provocative concentration induced a 20% decrease in FEV1 to house dust mite in asthmatic | By Comparison with methacholine provocation test | 30 mins and 24 hours after house dust mites bronchial challenge | |
Other | Incidence and Severity of Adverse Events During The House Dust Mite Bronchial Provocation Test | By Comparison with methacholine provocation test at 30 min and 24 hours after challenge test. | 30 minutes, 7 hours and 24 hours after house dust mites bronchial provocation | |
Primary | percentages of the participants that tested positive to house dust mites bronchial provocation | 30 minutes after house dust mites bronchial provocation | ||
Secondary | Changes of the percentages of eosinophils in sputum, nasal lavage and fractional exhaled nitric oxide (FeNO) from baseline | 30mins, 7 and 24 hours after bronchial challenge | ||
Secondary | Changes of provocative concentration induced a 20% decrease in forced expiratory volume at one second (FEV1) to methacholine before and after house dust mites bronchial provocation | 24 hours after house dust mites bronchial challenge | ||
Secondary | percentages of the participants that tested positive to house dust mites bronchial provocation measured by impulse oscillometry | 10 minutes after house dust mites bronchial provocation | ||
Secondary | Changes of provocative concentration induced a 60% increase in nasal airway resistance to histamine before and after house dust mites bronchial provocation | By Comparison with methacholine provocation test | 24 hours after house dust mites bronchial challenge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03850626 -
Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients
|
||
Completed |
NCT02911688 -
Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure
|
Phase 2 | |
Active, not recruiting |
NCT01776177 -
The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy
|
N/A | |
Completed |
NCT00485576 -
Safety and Efficacy Study of Eculizumab in Patients With Mild Allergic Asthma
|
Phase 2 | |
Completed |
NCT00736801 -
Effect of Salmeterol on Brain-Derived Neurotrophic Factor (BDNF) Concentrations in Asthma
|
N/A | |
Completed |
NCT00515775 -
Influence of a Inhaled Corticosteroid Therapy Versus Corticosteroid + LABA Therapy on the FeNO of Asthmatic Children
|
N/A | |
Completed |
NCT04259164 -
Anti-inflammatory Effects Glycopyrronium
|
Phase 3 | |
Active, not recruiting |
NCT04619017 -
Airway Immune Response to Allergens (Use Lay Language Here)
|
Phase 1 | |
Completed |
NCT01699594 -
Change in Airway Responsiveness After Allergen Exposure
|
N/A | |
Completed |
NCT01353755 -
2nd Pivotal Study rPhleum - Adults and Adolescents With Rhinoconjunctivitis +/-Controlled Asthma
|
Phase 3 | |
Completed |
NCT00999466 -
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
|
Phase 2 | |
Completed |
NCT00434434 -
A Study of Omalizumab in the Prevention of Allergen Induced Airway Obstruction in Adults With Mild Allergic Asthma
|
Phase 2 | |
Completed |
NCT00492076 -
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
|
Phase 4 | |
Completed |
NCT00490425 -
Prevention of Asthma and Allergy by Probiotic Lactobacillus GG
|
Phase 4 | |
Completed |
NCT00829179 -
Role of RhuMab-E25 in Reducing Exhaled Nitric Oxide (NO) in Allergic Asthma
|
Phase 3 | |
Recruiting |
NCT04542902 -
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
|
N/A | |
Recruiting |
NCT04109534 -
Effect of a Dietary Fatty Acid Supplementation on Symptoms and Bronchial Inflammation in Patients With Asthma
|
N/A | |
Active, not recruiting |
NCT05186025 -
Tyrosine Allergoid Paediatric and Adult Study
|
||
Withdrawn |
NCT03307278 -
House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance
|
N/A | |
Enrolling by invitation |
NCT06151938 -
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
|